These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17536889)

  • 41. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
    Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
    Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Evaluation model of the effect of Rofecoxib on the co-prescription of gastroprotective agents observed during the treatment of osteoarthritis].
    Russo P; Capone A; Baio G; Di Martino M; Degli Esposti L; Buda S; Degli Esposti E; Caprino L
    Reumatismo; 2002; 54(4):331-9. PubMed ID: 12563367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
    Moride Y; Ducruet T; Rochon S; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?
    Danda D; Iliyas MM; Chandy SJ; Chandra C; Mathew AJ
    Int J Rheum Dis; 2013 Feb; 16(1):24-9. PubMed ID: 23441769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of interventions by community pharmacists to reduce risk of gastrointestinal side effects in nonselective nonsteroidal anti-inflammatory drug users.
    Teichert M; Griens F; Buijs E; Wensing M; De Smet PA
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):382-9. PubMed ID: 24535837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prescription Pattern Analysis of Nonsteroidal Anti-inflammatory Drugs in the Northeastern Iranian Population.
    Zeinali M; Tabeshpour J; Maziar SV; Taherzadeh Z; Zirak MR; Sent D; Azarkhiavi KR; Eslami S
    J Res Pharm Pract; 2017; 6(4):206-210. PubMed ID: 29417079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX; Lee KY; Bertram CT; Goldstein JL
    Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Defined Daily Dose and Appropriateness of Clinical Application: The Coxibs and Traditional Nonsteroidal Anti-Inflammatory Drugs for Postoperative Orthopaedics Pain Control in a Private Hospital in Malaysia.
    Bakrin FS; Makmor-Bakry M; Che Hon WH; Faizal SM; Manan MM; Ming LC
    Pharmacy (Basel); 2020 Dec; 8(4):. PubMed ID: 33302438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector.
    Meuwesen WP; du Plessis JM; Burger JR; Lubbe MS; Cockeran M
    Int J Clin Pharm; 2016 Aug; 38(4):863-9. PubMed ID: 27091130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
    J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associations between prescribing nonsteroidal anti-inflammatory drugs and the potential prescription-related problems in a primary care setting.
    Dhabali AA; Awang R; Hamdan Z; Zyoud SH
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):851-61. PubMed ID: 23006441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.